L1CAM and relapsing-remitting multiple sclerosis: This study is the first to comprehensively characterize L1CAM+ EVs, assessing size, concentration, morphology, protein cargo, and surface immunophenotype, in both serum and CSF, while also evaluating their utility as dynamic biomarkers for anti-CD20 treatment response in RRMS.